AGRX Agile Therapeutics Inc.

-0.08  -10%
Previous Close 0.82
Open 0.83
Price To Book 1.1
Market Cap 25439223
Shares 34,377,329
Volume 646,170
Short Ratio
Av. Daily Volume 4,349,189

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL issued 2013. Further CRL issued December 22, 2017. Resubmission due 1H 2019 following completion of comparative wear study 1Q 2019.
Contraceptive patch

Latest News

  1. Agile Therapeutics, Inc. Meets With FDA on Comparative Wear Study of Twirla® and Xulane®
  2. Agile Therapeutics Inc (NASDAQ:AGRX): Are Analysts Optimistic?
  3. AGRX: Awaiting Details of Adhesion Study for Twirla®…
  4. Agile Therapeutics: 3Q Earnings Snapshot
  5. Agile Therapeutics Reports Third Quarter 2018 Financial Results
  6. Agile Therapeutics, Inc. Presents Additional Analyses of AG200-15 (Twirla®) Phase 3 SECURE Study Results at the 2018 North American Forum on Family Planning (NAFFP)
  7. Agile Therapeutics Gets a Path Forward for Twirla, Analysts Review and Target
  8. Today’s Research Reports on Stocks to Watch: Auris Medical Holding and Agile Therapeutics
  9. AGRX: FDA Provides Path to NDA Resubmission for Twirla®…
  10. Today's Research Reports on Trending Tickers: Agile Therapeutics and Horizon Pharma
  11. Agile Therapeutics, Inc. Completes Formal Dispute Resolution Process with the FDA
  12. Does Agile Therapeutics Inc (NASDAQ:AGRX) Fall With The Market?
  13. Today’s Research Reports on Stocks to Watch: Agile Therapeutics and BioPharmX
  14. New Growth Opportunities Jump for 3 Biotech Stocks in 2018
  15. AGRX: Formal Dispute Resolution Continues to Office of New Drugs…
  16. Complimentary Technical Snapshots on Akorn and Three More Generic Drugs Stocks

SEC Filings

  1. 8-K - Current report 181233710
  2. EFFECT - Notice of Effectiveness 181185871
  3. S-8 - Securities to be offered to employees in employee benefit plans 181157985
  4. S-3 - Registration statement under Securities Act of 1933 181157928
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 181155535
  6. 8-K - Current report 181154222
  7. 8-K - Current report 181135320
  8. 8-K - Current report 181112245
  9. 8-K - Current report 181110845
  10. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 181085946